Trial Profile
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 27 Jan 2024 Results of an analysis assessing tumor-infiltrating CD163-positive macrophages and clinical outcomes presented at the 2024 Genitourinary Cancers Symposium
- 24 Oct 2023 Results of pooled meta analysis from NCT03203473, NCT03117309, NCT02917772 assessing to better inform the activity of N+I after N presented at the 48th European Society for Medical Oncology Congress
- 06 Jun 2023 Results assessing biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.